[Inoperable primary bronchial cancers: treatment by chemotherapy combinations including cis-platinum].
Sixty-seven assessable patients with advanced primary bronchial carcinoma of the epidermoid or large cell undifferentiated type (37 with non-resectable stage III Mo and 30 with stage III M1) were included in two prospective non-randomized phase 2 chemotherapeutic trials. Thirty-five received a COPAC-type regimen and 32 were treated with a COPAB-RT protocol combining a COPAC-type chemotherapy with local radiotherapy. Both combination therapies contained cis-platinum. With either of these treatments the major response rate averaged 45% and the median survival rate was about 9 months. However, a significant (p = 0.03) difference in survival rate was elicited between the population of treated patients and a control group of 30 untreated patients of similar age, stage and histology (mean survival in controls: 5 months). Both chemotherapeutic regimens were regarded as reasonably well tolerated. These results suggest that platinum-based combination chemotherapy is effective in these carcinomas.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D002945:Cisplatin
Cancers bronchiques primitifs inopérables: traitement par combinaisons chimiothérapiques incluant le cis-platinum.